Phase III breast cancer study tests reduced post surgery therapy

The Alliance for Clinical Trials in Oncology has opened enrollment for a Phase III clinical trial named ShortStop HER2, according to Oncodaily. The study is led by Adrienne Waks at the Dana-Farber Cancer Institute. It focuses on patients with early stage HER2 positive breast cancer who have no remaining cancer following initial chemotherapy and targeted therapy. [1]

Oncodaily reported that many individuals who achieve a complete response to initial treatment still receive additional therapy after surgery. Clinical trials are prospective research studies on human participants designed to evaluate the safety and efficacy of medical interventions, according to Wikipedia. The new trial evaluates whether a shorter course of treatment can safely maintain positive health outcomes. [1][9]

HER2 is a protein encoded by the ERBB2 gene that resides in cell membranes, according to Wikipedia. Oncodaily noted that achieving a complete response after pre surgery treatment is associated with excellent long term outcomes. The trial, officially designated as study A012303, seeks to confirm if a less intensive approach remains effective. [1][10]